Originally called simply "Afghan Skunk" after its parents, a landrace Afghanistan Indica and the well loved Skunk #1, it was renamed Mazar in 1997.
Dutch Bred, Afghani Genetics
Mazar, a mostly Indica strain created by Dutch Passion, takes its name from Mazar-i-Sharif, a growing centre for cannabis in Afghanistan.
The smoke of this strain tastes of hash, fruit, citrus, and flowers. Its THC count reaches nearly 20% when the strain is grown properly. Users can experience the world in a bright and psychedelic light after using this strain, or they can fall into a deep sleep.
For most, this strain can be good for nighttime relief of insomnia as well as stimulation of appetite and easing of chronic pain. Mazar may also be prescribed for anxiety, stress, depression, bipolar disorder, and ADD/ADHD. Some find that it helps mitigate the symptoms of Alzheimer's disease, migraines, and headaches.
Since Mazar usually finishes flowering around the first week of November, the strain is better suited for an indoor grow. Inside, the strain will flower between eight and nine weeks and reach about a meter in height. Particularly well suited for the Screen of Green method, these plants will need to be supported during the flowering period.
Description provided by Wikileaf.
Information provided could come from a third-party source, and likely does not accurately reflect characteristics of the medication we're associating it with - we primarily provide these descriptions for those interested in strain lineage and history, which could also be inaccurate. Any information which could be taken as medical advice should be strictly disregarded. Please consult your doctor regarding the suitability of medications for your condition(s).
About Lyphe Group Ltd
From Lyphe Group, a range of medical flowers and oils focused on giving doctors reassurance in the efficiency and consistency of our supply chain, while providing quality pharmaceutical-grade medication.
At Lyphe our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.lyphegroup.com